Valuation: Nuvalent, Inc.

Market Cap 9.83B 8.86B 8.19B 7.4B 14.01B 922B 14.35B 98.14B 39.12B 494B 36.91B 36.12B 1,572B P/E 2024
-19.9x
P/E 2025 -17.2x
Enterprise Value 8.46B 7.63B 7.05B 6.37B 12.05B 794B 12.35B 84.45B 33.66B 425B 31.76B 31.08B 1,353B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
88.66%
Yield 2024 *
-
Yield 2025 -

Last Transcript: Nuvalent, Inc.

1 day+0.02%
6 months+18.57%
Current year+23.23%
Current year 87.3
Extreme 87.3
123.99
1 year 87.3
Extreme 87.3
123.99
3 years 55.33
Extreme 55.33
123.99
5 years 7.09
Extreme 7.09
123.99
10 years 7.09
Extreme 7.09
123.99
Manager TitleAgeSince
President - 2026-07-14
Director TitleAgeSince
Director/Board Member - 2026-07-14
Date Insider Type Main position Quantity % Market Cap. Importance
7/15/26 Tender

Director

-120,026 0.1784%
7/15/26 Tender

Director

-79,887 0.1188%
7/15/26 Tender

Director

-18,289 0.0272%
Change 5-day change 1-year change 3-year change Capi.($)
+0.02%-.--%+28.92%+118.05% 9.83B
-1.06%-0.07%+60.76%+68.61% 68.32B
+1.30%+7.41%+14.79%+92.69% 60.26B
+0.39%+0.30%+20.04%+98.33% 55.86B
-0.95%+11.17%+22.21%+110.93% 48.43B
-0.23%+4.07%+25.63%+40.08% 45.34B
-6.40%-9.51%+181.99%+816.79% 41.76B
+1.97%+3.50%+25.78%+50.98% 34.5B
-0.56%-0.48%+85.57%+65.40% 33.8B
+1.05%+9.77%-37.66%+408.42% 26.21B
Average -0.45%+1.32%+42.80%+187.03% 42B
Weighted average by Cap. -0.52%+1.41%+44.96%+171.80%

Financials

2024 2025
Net sales - -
Net income -261M -235M -217M -196M -371M -24.46B -381M -2.6B -1.04B -13.1B -979M -958M -41.68B -425M -383M -354M -320M -606M -39.9B -621M -4.25B -1.69B -21.37B -1.6B -1.56B -68B
Net Debt -1.12B -1.01B -931M -842M -1.59B -105B -1.63B -11.16B -4.45B -56.17B -4.2B -4.11B -179B -1.37B -1.24B -1.14B -1.03B -1.95B -129B -2B -13.69B -5.46B -68.91B -5.15B -5.04B -219B
Projected Income Statement - Annual - Nuvalent, Inc.
Logo Nuvalent, Inc.
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. It develops small molecules that have the potential to overcome resistance, minimize adverse events, and address brain metastases. It is advancing a robust pipeline with investigational candidates for ROS proto-oncogene 1 (ROS1)-positive, anaplastic lymphoma kinase (ALK)-positive, and human epidermal growth factor receptor 2 (HER2)-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, Zidesamtinib (NVL-520), is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, Neladalkib (NVL-655), is being developed for patients with ALK-positive NSCLC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant HER2-selective inhibitor.
Employees
234
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
MarketScreener Ratings - Nuvalent, Inc.
  1. Stock Market
  2. Stocks
  3. NUVL Stock